Research programme: hyper IgE syndrome gene therapies - Cellectis
Alternative Names: Research programme: hyperimmunoglobulinemia E gene therapies - CellectisLatest Information Update: 06 Jul 2021
At a glance
- Originator Cellectis
- Developer Cellectis; University of Freiburg
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Job syndrome